1Mclaughlin P,Antonin J,Grillo- Lopez A J,et al. Rituximab chimeric anti - CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four- dose treatment porgram[J]. J Clin Oncol. 1998,16(8) :2825.
2Hainsworth A, Lam T, Alas, et al. Chimeric anti - CD20(IDEC- C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs[J].Cancer Biotherapy and Radiopharma ceuticals. 1997, 12:177.
3Vose J M,Link B K,Grossbard M L,et al. Phase Ⅱ Study of Rituximab in Combination With CHOP Chemotherapy in Patients With Previously Untreated, Aggressive NonHodgkin' s Lymphoma [J]. J Clin Oncol. 2001, 19 (2):389.
4Czucman M S,Grillo- Lopez A J ,White C A. Treatment of patients with low - grade B - cell lymphoma with the combination of chimeric anti - CD20 monoclonal antibody and CHOP chemeotherapy[J]. J Clin Oncol. 1999,17(1):268.
5Sievers E L, Larson R A, Stadmauer E A, et al. Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33 - Positive Acute Myeloid Leukemia in First Relapse [J ]. J Clin Oncol. 2001,19(3): 3244.
6Larson R A, Boogaerts M, Estey E, et al. Antibody- targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin) [J]. Leukemia. 2002,16(9): 1627.
7Osterborg A,Dyer M J,Bunjes D,et al. Phase Ⅱ multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH- 1H Treatment in Chronic Lymphocytic Leukemia[J]. J Clin Oncol. 1997,15(4): 1567.
8Dearden C E, Matutes E, Cazin b, et al. High remission rate in T - cell prolymphocytic leukemia with CAMPATH- 1H[J]. Blood. 2001,98(6): 1721.
9Cobleigh M, Vogel C L, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti - HER - 2 monoclonal anti - body in women who have HER - 2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease [J]. J Clin Oncol. 1999,17(9) :2639～2648.
10Norton L, Slamon D, Leyland - Jones B, et al. Overall survival(OS) advantage to simultaneous chemotheragy (CRx) plue the humanized anti - HER - 2monclonal anti- body Herceptin(H) in HER - 2 - overexpressing (HER - 2 + ) metastatic breast cancer (MBC) [J ]. Proc Am Soc Clin Oncol. 1999,18:127a.
